John D. Baird, PhD (he/him/his)

CoS
PTC Therapeutics, Inc.
South Plainfield, New Jersey, United States

Presentation(s):

• Paper 17 - A PHASE 1B STUDY OF UNESBULIN (PTC596) PLUS DACARBAZINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED LEIOMYOSARCOMA

  Thursday, November 17, 2022
  1:00 PM – 1:08 PM